Graft Polymer (UK) - Directorate Change

Solvonis Therapeutics

01/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240801:nRSA6631Ya&default-theme=true

RNS Number : 6631Y  Graft Polymer (UK) PLC  01 August 2024

01 August 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

 

Director resignation

 

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery
systems development company, announces the resignation, with immediate effect,
of Mr. Victor Bolduev from its board of directors and from his role as the
Company's Chief Technology Officer.  Mr Bolduev's resignation follows :

a)   the Company's divestiture of its industrial plastics business unit,
Graft Polymer D.O.O., in  early May 2024; and

 

b)   the Company's prioritisation of opportunities in the healthcare
industry, including the recently announced collaboration agreement with Awakn
Life Sciences Corp (CSE:AWKN OTCQB:AWKNF) and the appointment, on 30 July
2024, of Professor David Nutt as the Company's Senior Scientific Adviser.

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director

Email: anthonytennyson@graftpolymer.co.uk

Yifat Steuer, CFO and Executive Director

Email: yifat@graftpolymer.co.uk

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

+44 (0) 20 3328 5656

 

 

About Graft Polymer (UK) Plc

Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer
drug delivery systems development company dedicated to enabling
biopharmaceutical companies to enhance the effectiveness of their
therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying
drug delivery system (SNEDDS), represents a cutting-edge solution in drug
delivery technology. By integrating active pharmaceutical ingredients (APIs)
into our novel, patented delivery systems, we enable clients to improve the
pharmacokinetics, bioavailability, and stability of their therapeutics..

 

For more information, please visit www.graftpolymer.co.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDRDBXDGSB